## Stephen P Mcdonald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/527844/publications.pdf

Version: 2024-02-01

242 papers

12,436 citations

23879 60 h-index 37326 100 g-index

244 all docs 244 docs citations

times ranked

244

10312 citing authors

#	Article	IF	CITATIONS
1	Factors influencing fertility rates in Australian women receiving kidney replacement therapy: analysis of linked Australia and New Zealand Dialysis and Transplant Registry and perinatal data over 22 years. Nephrology Dialysis Transplantation, 2022, 37, 1152-1161.	0.4	13
2	Mortality After Home Hemodialysis Treatment Failure and Return to In-Center Hemodialysis. American Journal of Kidney Diseases, 2022, 79, 15-23.e1.	2.1	8
3	Changes in excess mortality among adults with diabetes-related end-stage kidney disease: a comparison between the USA and Australia. Nephrology Dialysis Transplantation, 2022, 37, 2004-2013.	0.4	3
4	Representativeness of the PDOPPS cohort compared to the Australian PD population. Peritoneal Dialysis International, 2022, 42, 403-414.	1.1	2
5	Healthcare professional and community preferences in deceased donor kidney allocation: A best-worst scaling survey. American Journal of Transplantation, 2022, 22, 886-897.	2.6	4
6	Perspectives of Patients, Nurses, and Nephrologists About Electronic Symptom Monitoring With Feedback in Hemodialysis Care. American Journal of Kidney Diseases, 2022, 80, 215-226.e1.	2.1	5
7	Interactions Between Donor Age and 12-Month Estimated Glomerular Filtration Rate on Allograft and Patient Outcomes After Kidney Transplantation. Transplant International, 2022, 36, 10199.	0.8	3
8	Excess allâ€cause and causeâ€specific mortality for people with diabetes and endâ€stage kidney disease. Diabetic Medicine, 2022, 39, e14775.	1.2	2
9	Multifaceted intervention to reduce haemodialysis catheter related bloodstream infections: REDUCCTION stepped wedge, cluster randomised trial. BMJ, The, 2022, 377, e069634.	3.0	6
10	Associations between diabetes and sex with peritoneal dialysis technique and patient survival: Results from the Australia and New Zealand Dialysis and Transplant Registry cohort study. Peritoneal Dialysis International, 2021, 41, 57-68.	1.1	10
11	Pregnancy outcomes for simultaneous Pancreas–Kidney transplant recipients versus kidney transplant recipients. Clinical Transplantation, 2021, 35, e14151.	0.8	5
12	The psychosocial experiences and supportive care preferences of organ transplant recipients and their carers who live in regional Australia. Australian Journal of Rural Health, 2021, 29, 92-105.	0.7	9
13	Center-Effect of Incident Hemodialysis Vascular Access Use: Analysis of a Bi-national Registry. Kidney360, 2021, 2, 674-683.	0.9	2
14	Survival and transplant outcomes among young children requiring kidney replacement therapy. Pediatric Nephrology, 2021, 36, 2443-2452.	0.9	7
15	Gastrointestinal symptom burden and dietary intake in patients with chronic kidney disease. Journal of Renal Care, 2021, 47, 234-241.	0.6	2
16	Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Diabetes Care, 2021, 44, 1515-1523.	4.3	11
17	Home Versus Facility Dialysis and Mortality in Australia and New Zealand. American Journal of Kidney Diseases, 2021, 78, 826-836.e1.	2.1	10
18	The prevalence and evidence-based management of needle fear in adults with chronic disease: A scoping review. PLoS ONE, 2021, 16, e0253048.	1.1	23

#	Article	IF	CITATIONS
19	Serum phosphate and mortality in incident dialysis patients in Australia and New Zealand. Nephrology, 2021, 26, 814-823.	0.7	6
20	The IDEAL trial in Australia and New Zealand: clinical and economic impact. Nephrology Dialysis Transplantation, 2021, 37, 168-174.	0.4	1
21	Socioâ€economic disparity, access to care and patientâ€relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	0.8	2
22	Obesity in dialysis patients – What is the problem?. Obesity Research and Clinical Practice, 2021, 15, 413-414.	0.8	1
23	Shifting Power to Improve First Nation Peoples' Access and Outcomes in Kidney Care. Kidney Medicine, 2021, 3, 881-882.	1.0	5
24	A retrospective caseâ€control study exploring preâ€transplant predictors for loss of kidney transplant function or death among Indigenous kidney transplant recipients. Internal Medicine Journal, 2021, , .	0.5	0
25	Principles and strategies for involving patients in research in chronic kidney disease: report from national workshops. Nephrology Dialysis Transplantation, 2020, 35, 1585-1594.	0.4	14
26	Impact of supplemental private health insurance on dialysis and outcomes. Internal Medicine Journal, 2020, 50, 542-549.	0.5	3
27	Insights into the labeling effect of Kidney Donor Performance Index reporting: The Australian experience. American Journal of Transplantation, 2020, 20, 870-878.	2.6	3
28	Two pregnancies after simultaneous pancreas–kidney transplantation: A case report. Obstetric Medicine, 2020, 13, 92-95.	0.5	6
29	International collaborative efforts to establish kidney health surveillance systems. Kidney International, 2020, 98, 812-816.	2.6	12
30	ABO blood group relationships to kidney transplant recipient and graft outcomes. PLoS ONE, 2020, 15, e0236396.	1.1	3
31	Novel trial strategies to enhance the relevance, efficiency, effectiveness, and impact of nephrology research. Kidney International, 2020, 98, 572-578.	2.6	5
32	The Association Between Age of Onset of Type 2 Diabetes and the Long-term Risk of End-Stage Kidney Disease: A National Registry Study. Diabetes Care, 2020, 43, 1788-1795.	4.3	28
33	REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach (REDUCCTION) – design and baseline results. Kidney360, 2020, 1, 746-754.	0.9	8
34	Fatherhood and Kidney Replacement Therapy: Analysis of the Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry. American Journal of Kidney Diseases, 2020, 76, 444-446.	2.1	4
35	Feasibility and acceptability of e-PROMs data capture and feedback among patients receiving haemodialysis in the Symptom monitoring WIth Feedback Trial (SWIFT) pilot: protocol for a qualitative study in Australia. BMJ Open, 2020, 10, e039014.	0.8	16
36	FO031THE SYMPTOM MONITORING WITH FEEDBACK TRIAL (SWIFT): A NOVEL REGISTRY-BASED CLUSTER RANDOMISED CONTROLLED TRIAL AMONG AUSTRALIAN AND NEW ZEALAND ADULTS WITH END-STAGE KIDNEY DISEASE MANAGED ON HAEMODIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	2

3

#	Article	IF	CITATIONS
37	Long-Term Outcomes after Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis. Journal of the American Society of Nephrology: JASN, 2019, 30, 1697-1707.	3.0	84
38	Weight change trajectories in Aboriginal and Torres Strait islander Australians after kidney transplantation: a cohort analysis using the Australia and New Zealand Dialysis and Transplant registry (ANZDATA). BMC Nephrology, 2019, 20, 232.	0.8	7
39	Impending challenges of the burden of endâ€stage kidney disease in Australia. Medical Journal of Australia, 2019, 211, 374.	0.8	10
40	International travel by Australians for overseas transplantation. Medical Journal of Australia, 2019, 211, 460-460.	0.8	0
41	Infection-Related Mortality in Recipients of a Kidney Transplant in Australia and New Zealand. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1484-1492.	2.2	29
42	Using the excess heat factor to indicate heatwave-related urinary disease: a case study in Adelaide, South Australia. International Journal of Biometeorology, 2019, 63, 435-447.	1.3	29
43	Daily hemodialysis practices in Australia/New Zealand and in France: a comparative cohort study. BMC Nephrology, 2019, 20, 156.	0.8	4
44	Quantifying lead time bias when estimating patient survival in preemptive living kidney donor transplantation. American Journal of Transplantation, 2019, 19, 3367-3376.	2.6	12
45	External validation of the US and UK kidney donor risk indices for deceased donor kidney transplant survival in the Australian and New Zealand population. Nephrology Dialysis Transplantation, 2019, 34, 2127-2131.	0.4	24
46	Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients. Circulation, 2019, 139, 2809-2818.	1.6	71
47	The Spectrum of Adverse Pregnancy Outcomes Based on Kidney Disease Diagnoses: A 20-Year Population Study. American Journal of Nephrology, 2019, 49, 400-409.	1.4	18
48	Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. Journal of the American Society of Nephrology: JASN, 2019, 30, 471-480.	3.0	81
49	Response by Rao et al to Letter Regarding Article, "Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients― Circulation, 2019, 140, e806-e807.	1.6	0
50	Access to waitlisting for deceased donor kidney transplantation in Australia. Nephrology, 2019, 24, 758-766.	0.7	25
51	Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. American Journal of Kidney Diseases, 2019, 73, 300-308.	2.1	33
52	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, 2018, 72, 62-74.	2.1	39
53	Report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure forÂHemodialysis Vascular Access. American Journal of Kidney Diseases, 2018, 71, 690-700.	2.1	62
54	Direct and indirect costs incurred by Australian living kidney donors. Nephrology, 2018, 23, 1145-1151.	0.7	8

#	Article	IF	CITATIONS
55	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2018, 38, 257-265.	1.1	12
56	Bowel health in chronic kidney disease: Patient perceptions differ from clinical definitions. Journal of Renal Care, 2018, 44, 65-72.	0.6	7
57	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. American Journal of Kidney Diseases, 2018, 71, 814-821.	2.1	66
58	Ageâ€specific risk of renal graft loss from late acute rejection or nonâ€compliance in the adolescent and young adult period. Nephrology, 2018, 23, 585-591.	0.7	23
59	Projecting demands for renal replacement therapy in the Northern Territory: a stochastic Markov model. Australian Health Review, 2018, 42, 380.	0.5	6
60	Indigenous patient experiences of returning to country: a qualitative evaluation on the Country Health SA Dialysis bus. BMC Health Services Research, 2018, 18, 1010.	0.9	21
61	Disparity of access to kidney transplantation by Indigenous and nonâ€Indigenous Australians. Medical Journal of Australia, 2018, 209, 261-266.	0.8	38
62	The Relationship between Body Mass Index and Organism-Specific Peritonitis. Peritoneal Dialysis International, 2018, 38, 206-214.	1.1	9
63	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. American Journal of Kidney Diseases, 2017, 70, 464-475.	2.1	218
64	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 397-406.	1.1	14
65	The Impact of Total Ischemic Time, Donor Age and the Pathway of Donor Death on Graft Outcomes After Deceased Donor Kidney Transplantation. Transplantation, 2017, 101, 1152-1158.	0.5	65
66	Obesity in pediatric kidney transplant recipients and the risks of acute rejection, graft loss and death. Pediatric Nephrology, 2017, 32, 1443-1450.	0.9	27
67	Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. Lancet Diabetes and Endocrinology,the, 2017, 5, 26-33.	5.5	57
68	Kidney Disease Among Aboriginal and Torres Strait Islander People in Australia. , 2017, , 167-180.		3
69	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2017, 37, 619-626.	1.1	18
70	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation. Transplantation, 2017, 101, 1875-1886.	0.5	68
71	Editorial: RRT in South Africa - and the relevance of Registries. Nephrology, 2017, 22, 581-582.	0.7	0
72	Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014). Population Health Metrics, 2017, 15, 7.	1.3	15

#	Article	IF	Citations
73	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop. American Journal of Kidney Diseases, 2017, 69, 97-107.	2.1	148
74	Organ Transplantation in Australia. Transplantation, 2017, 101, e345-e346.	0.5	11
75	The impact of daily temperature on renal disease incidence: an ecological study. Environmental Health, 2017, 16, 114.	1.7	85
76	Residential Location and Kidney Transplant Outcomes in Indigenous Compared With Nonindigenous Australians. Transplantation, 2016, 100, 2168-2176.	0.5	20
77	Risk-Factor Profile of Living Kidney Donors. Transplantation, 2016, 100, 1278-1283.	0.5	28
78	Dialysis modality, vascular access and mortality in endâ€stage kidney disease: A biâ€national registryâ€based cohort study. Nephrology, 2016, 21, 878-886.	0.7	15
79	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney International, 2016, 89, 1337-1345.	2.6	44
80	Center-Specific Factors Associated with Peritonitis Riskâ€"A Multi-Center Registry Analysis. Peritoneal Dialysis International, 2016, 36, 509-518.	1.1	54
81	Duration of Hemodialysis following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. Peritoneal Dialysis International, 2016, 36, 623-630.	1.1	71
82	The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation. Transplantation Direct, 2016, 2, e120.	0.8	29
83	Intensive Hemodialysis and Mortality Risk in Australian andÂNewÂZealand Populations. American Journal of Kidney Diseases, 2016, 67, 617-628.	2.1	42
84	Maternal compared with paternal donor kidneys are associated with poorer graft outcomes after kidney transplantation. Kidney International, 2016, 89, 659-665.	2.6	7
85	Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials, 2015, 16, 364.	0.7	67
86	Living Kidney Donor Outcomesâ€"More Pieces to the Jigsaw. Transplantation, 2015, 99, 1547-1548.	0.5	0
87	Clustering and Residual Confounding in the Application of Marginal Structural Models: Dialysis Modality, Vascular Access, and Mortality. American Journal of Epidemiology, 2015, 182, 535-543.	1.6	12
88	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. American Journal of Kidney Diseases, 2015, 66, 489-498.	2.1	41
89	Australia and New Zealand Dialysis and Transplant Registry. Kidney International Supplements, 2015, 5, 39-44.	4.6	65
90	Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 450-459.	1.1	16

#	Article	IF	Citations
91	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	1.1	37
92	Pregnancy Outcomes According to Dialysis Commencing Before or After Conception in Women with ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 143-149.	2.2	120
93	Progression of polycystic kidney diseaseâ€"a lack of progress?. Nature Reviews Nephrology, 2014, 10, 489-491.	4.1	1
94	Dialysis outcomes of elderly <scp>I</scp> ndigenous and nonâ€ <scp>I</scp> ndigenous <scp>A</scp> ustralians. Nephrology, 2014, 19, 610-616.	0.7	7
95	Racial disparities in pediatric kidney transplantation in $\langle scp \rangle N \langle scp \rangle ew \langle scp \rangle Z \langle scp \rangle ealand$ . Pediatric Transplantation, 2014, 18, 689-697.	0.5	20
96	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. Nephrology Dialysis Transplantation, 2014, 29, 1940-1947.	0.4	34
97	Placing Aboriginal kidney disease in context. Cmaj, 2014, 186, 93-94.	0.9	4
98	Socioeconomic Differences in the Uptake of Home Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 929-935.	2.2	35
99	Racial disparities in paediatric kidney transplantation. Pediatric Nephrology, 2014, 29, 125-132.	0.9	20
100	The Association between Peritoneal Dialysis Modality and Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1091-1097.	2.2	49
101	Estimating the Total Incidence of Kidney Failure in Australia Including Individuals Who Are Not Treated by Dialysis or Transplantation. American Journal of Kidney Diseases, 2013, 61, 413-419.	2.1	54
102	Australian registries—ANZDATA and ANZOD. Transplantation Reviews, 2013, 27, 46-49.	1.2	41
103	Prevalence of genetic renal disease in children. Pediatric Nephrology, 2013, 28, 251-256.	0.9	35
104	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. American Journal of Kidney Diseases, 2013, 61, 96-103.	2.1	48
105	DCD ECD Kidneysâ€"Can You Make a Silk Purse From a Sow's Ear?. American Journal of Transplantation, 2013, 13, 249-250.	2.6	9
106	The Outcomes of Patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 773-780.	2.2	43
107	Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney International, 2013, 83, 503-510.	2.6	59
108	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1556-1563.	2.2	26

#	Article	IF	Citations
109	Does equal care give equal outcomes?. Kidney International, 2013, 84, 647-650.	2.6	4
110	End-stage kidney disease among indigenous peoples of Australia and New Zealand. Kidney International Supplements, 2013, 3, 170-173.	4.6	21
111	Postâ€transplant lymphoproliferative disorder: No relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients. Pediatric Transplantation, 2013, 17, 731-736.	0.5	17
112	Estimated GFR Reporting Influences Recommendations for Dialysis Initiation. Journal of the American Society of Nephrology: JASN, 2013, 24, 1737-1742.	3.0	6
113	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. Peritoneal Dialysis International, 2013, 33, 75-85.	1.1	17
114	Transplantation rates for living- but not deceased-donor kidneys vary with socioeconomic status in Australia. Kidney International, 2013, 83, 138-145.	2.6	51
115	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrology Dialysis Transplantation, 2013, 28, 455-461.	0.4	37
116	Peritoneal dialysis in rural Australia. BMC Nephrology, 2013, 14, 278.	0.8	20
117	Outcomes of Kidney Transplantation From Older Living Donors. Transplantation, 2013, 95, 106-113.	0.5	54
118	Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrology Dialysis Transplantation, 2012, 27, 3581-3587.	0.4	75
119	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1398-1405.	3.0	198
120	Risk Factors for Dialysis Withdrawal. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 775-781.	2.2	36
121	Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy. BMJ, The, 2012, 345, e4657-e4657.	3.0	40
122	Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrology Dialysis Transplantation, 2012, 27, 381-387.	0.4	38
123	Weekend Compared with Weekday Presentations of Peritoneal Dialysis–Associated Peritonitis. Peritoneal Dialysis International, 2012, 32, 516-524.	1.1	16
124	Socio-economic status and incidence of renal replacement therapy: a registry study of Australian patients. Nephrology Dialysis Transplantation, 2012, 27, 4173-4180.	0.4	43
125	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. Nephrology Dialysis Transplantation, 2012, 27, 2028-2036.	0.4	31
126	Renal replacement therapy in rural and urban Australia. Nephrology Dialysis Transplantation, 2012, 27, 2069-2076.	0.4	40

#	Article	IF	CITATIONS
127	Mycophenolate Versus Azathioprine for Kidney Transplantation. Transplantation, 2012, 94, 152-158.	0.5	49
128	End-stage kidney disease due to haemolytic uraemic syndrome – outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrology, 2012, 13, 164.	0.8	7
129	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. BMC Nephrology, 2012, 13, 41.	0.8	27
130	Increases in renal replacement therapy in Australia and New Zealand: Understanding trends in diabetic nephropathy. Nephrology, 2012, 17, 76-84.	0.7	64
131	Repeated Peritoneal Dialysis–Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2012, 59, 84-91.	2.1	19
132	Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients. Clinical Transplantation, 2012, 26, E428-37.	0.8	84
133	Lack of impact of donor age on patient survival for renal transplant recipients ≥60 years. Transplant International, 2012, 25, 401-408.	0.8	7
134	Association between initial and pretransplant dialysis modality and graft and patient outcomes in liveand deceased-donor renal transplant recipients. Transplant International, 2012, 25, 1032-1040.	0.8	4
135	Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients. Nephrology, 2012, 17, 458-465.	0.7	16
136	Secular Trends in Cardiovascular Mortality Rates of Patients Receiving Dialysis Compared With the General Population. American Journal of Kidney Diseases, 2011, 58, 64-72.	2.1	110
137	Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy. Human Immunology, 2011, 72, 386-391.	1.2	29
138	A review of utilityâ€based allocation strategies to maximize graft years of deceased donor kidneys. Nephrology, 2011, 16, 368-376.	0.7	6
139	Morbidity burden of endâ€stage kidney disease in Australia: Hospital separation rates among people receiving kidney replacement therapy. Nephrology, 2011, 16, 758-766.	0.7	11
140	International quotidian dialysis registry: Annual report 2010. Hemodialysis International, 2011, 15, 15-22.	0.4	16
141	Barriers to Timely Arteriovenous Fistula Creation: A Study of Providers and Patients. American Journal of Kidney Diseases, 2011, 57, 873-882.	2.1	76
142	Relapsing and Recurrent Peritoneal Dialysis–Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2011, 58, 429-436.	2.1	63
143	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. American Journal of Kidney Diseases, 2011, 58, 782-793.	2.1	168
144	Risk of Tuberculosis in Dialysis Patients: A Nationwide Cohort Study. PLoS ONE, 2011, 6, e29563.	1.1	66

#	Article	IF	CITATIONS
145	End-stage kidney disease due to sclerodermaoutcomes in 127 consecutive ANZDATA registry cases. Nephrology Dialysis Transplantation, 2011, 26, 3165-3171.	0.4	33
146	Microbiology and Outcomes of Peritonitis in Australian Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2011, 31, 651-662.	1.1	183
147	Compared with Younger Peritoneal Dialysis Patients, Elderly Patients have Similar Peritonitis-Free Survival and Lower Risk of Technique Failure, but Higher Risk of Peritonitis-Related Mortality. Peritoneal Dialysis International, 2011, 31, 663-671.	1.1	66
148	Effect of donor-recipient age difference on graft function and survival in live-donor kidney transplantation. Nephrology Dialysis Transplantation, 2011, 26, 702-708.	0.4	54
149	Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality. Nephrology Dialysis Transplantation, 2011, 26, 3366-3372.	0.4	56
150	Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. Clinical Science, 2011, 120, 263-283.	1.8	188
151	Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2657-2661.	2.2	6
152	Reduction in Cardiovascular Death After Kidney Transplantation. Transplantation, 2010, 89, 851-857.	0.5	181
153	Epidemiology and outcomes of peritonitis in children on peritoneal dialysis in Australasia. Pediatric Nephrology, 2010, 25, 1739-1745.	0.9	25
154	Polymicrobial Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes. American Journal of Kidney Diseases, 2010, 55, 121-131.	2.1	80
155	Culture-Negative Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes in 435 Cases. American Journal of Kidney Diseases, 2010, 55, 690-697.	2.1	85
156	No excess risk of follicular lymphoma in kidney transplant and HIVâ€related immunodeficiency. International Journal of Cancer, 2010, 127, 2732-2735.	2.3	19
157	Comparable transplant outcomes between local and shipped deceasedâ€donor kidneys in Australia: Analysis of Australia and New Zealand Dialysis and Transplant Registry 1992–2007. Nephrology, 2010, 15, 124-132.	0.7	6
158	Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients. Nephrology, 2010, 15, 368-376.	0.7	19
159	Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transplant International, 2010, 23, 1207-1215.	0.8	9
160	Home haemodialysis in Australia — is the wheel turning full circle?. Medical Journal of Australia, 2010, 192, 403-406.	0.8	22
161	Staphylococcus Aureus Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment, and Outcomes in 503 Cases. Peritoneal Dialysis International, 2010, 30, 311-319.	1.1	84
162	Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. Nephrology Dialysis Transplantation, 2010, 25, 1272-1278.	0.4	70

#	Article	IF	Citations
163	Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2010, 25, 1973-1979.	0.4	84
164	Donor-recipient age matching improves years of graft function in deceased-donor kidney transplantation. Nephrology Dialysis Transplantation, 2010, 25, 3082-3089.	0.4	40
165	Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ: British Medical Journal, 2010, 340, c570-c570.	2.4	149
166	Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney International, 2010, 77, 904-912.	2.6	154
167	Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. Nephrology Dialysis Transplantation, 2010, 25, 3386-3392.	0.4	60
168	Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. Kidney International, 2010, 78, 408-414.	2.6	62
169	Open and Laparoscopic Donor Nephrectomy: Activity and Outcomes From all Australasian Transplant Centers. Transplantation, 2010, 89, 1482-1488.	0.5	16
170	Peritoneal Small Solute Clearance is Nonlinearly Related to Patient Survival in the Australian and New Zealand Peritoneal Dialysis Patient Populations. Peritoneal Dialysis International, 2009, 29, 637-646.	1.1	35
171	Pseudomonas Peritonitis in Australia. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 957-964.	2.2	92
172	Relationship between Dialysis Modality and Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 155-163.	3.0	282
173	Association of Dialysis Modality and Cardiovascular Mortality in Incident Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1620-1628.	2.2	85
174	Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation. Kidney International, 2009, 76, 659-664.	2.6	103
175	Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney International, 2009, 76, 622-628.	2.6	134
176	Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. Nephrology Dialysis Transplantation, 2009, 24, 3834-3839.	0.4	46
177	The pattern of excess cancer in dialysis and transplantation. Nephrology Dialysis Transplantation, 2009, 24, 3225-3231.	0.4	174
178	Recovery of renal function in end-stage renal failure-comparison between peritoneal dialysis and haemodialysis. Nephrology Dialysis Transplantation, 2009, 24, 2825-2831.	0.4	31
179	Immunosuppression and Other Risk Factors for Lip Cancer after Kidney Transplantation. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 561-569.	1.1	<b>7</b> 3
180	Associations of Dialysis Modality and Infectious Mortality in Incident Dialysis Patients in Australia and New Zealand. American Journal of Kidney Diseases, 2009, 53, 290-297.	2.1	112

#	Article	IF	CITATIONS
181	Frequency, etiology and treatment of childhood end-stage kidney disease in Australia and New Zealand. Pediatric Nephrology, 2009, 24, 1719-1726.	0.9	60
182	Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. BMC Nephrology, 2009, 10, 19.	0.8	52
183	International quotidian dialysis registry: Annual report 2009. Hemodialysis International, 2009, 13, 240-249.	0.4	19
184	The costâ€effectiveness of increasing kidney transplantation and homeâ€based dialysis. Nephrology, 2009, 14, 123-132.	0.7	166
185	Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2297-2303.	1.1	66
186	The Case of Azathioprine Versus Mycophenolate. Do Different Drugs Really Cause Different Transplant Outcomes?. Transplantation, 2009, 87, 803-804.	0.5	9
187	Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood, 2009, 114, 630-637.	0.6	115
188	Outcomes of Transplantation Using Kidneys From Donors Meeting Expanded Criteria in Australia and New Zealand, 1991 to 2005. Transplantation, 2009, 87, 1201-1209.	0.5	33
189	Interleukin-2 Receptor Antibody Reduces Rejection Rates and Graft Loss in Live-Donor Kidney Transplant Recipients. Transplantation, 2009, 88, 1208-1213.	0.5	9
190	The International Quotidian Dialysis Registry: Annual report 2008. Hemodialysis International, 2008, 12, 281-289.	0.4	10
191	Home hemodialysis in Australia: Current perspective. Hemodialysis International, 2008, 12, S6-S10.	0.4	21
192	Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991–2005. Nephrology, 2008, 13, 171-176.	0.7	17
193	Preâ€emptive renal transplantation from living donors in Australia: Effect on allograft and patient survival. Nephrology, 2008, 13, 535-540.	0.7	30
194	Post-Kidney Transplant Weight Change as Marker of Poor Survival Outcomes. Transplantation, 2008, 85, 1443-1448.	0.5	52
195	High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis. Nephrology Dialysis Transplantation, 2007, 22, 3005-3012.	0.4	14
196	Increased Incidence of Squamous Cell Carcinoma of Eye After Kidney Transplantation. Journal of the National Cancer Institute, 2007, 99, 1340-1342.	3.0	35
197	Parental Donors in Live-Donor Kidney Transplantation Associated With Increased Rejection Rates and Reduced Glomerular Filtration Rates. Transplantation, 2007, 84, 972-980.	0.5	19
198	Trends in Kidney Transplantation in Australia and New Zealand, 1993–2004. Transplantation, 2007, 84, 611-618.	0.5	68

#	Article	IF	CITATIONS
199	Effects of Body Mass Index at Transplant on Outcomes of Kidney Transplantation. Transplantation, 2007, 84, 981-987.	0.5	170
200	Predictors of Renal Recovery in Australian and New Zealand end-Stage Renal Failure Patients Treated with Peritoneal Dialysis. Peritoneal Dialysis International, 2007, 27, 184-191.	1.1	29
201	Isolated sphenoid fungal sinusitis in a renal transplant recipient presenting with bilateral abducens nerve palsy. Transplant International, 2007, 20, 640-642.	0.8	6
202	Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20?64�years in Europe, Canada and the Asia-Pacific region, 1998?2002. Nephrology, 2007, 12, 520-527.	0.7	40
203	Trends in Hemodialysis Vascular Access From the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) 2000 to 2005. American Journal of Kidney Diseases, 2007, 50, 612-621.	2.1	29
204	Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis. Peritoneal Dialysis International, 2007, 27, 184-91.	1.1	12
205	Cancer Incidence Before and After Kidney Transplantation. JAMA - Journal of the American Medical Association, 2006, 296, 2823.	3.8	953
206	Recurrence of IgA Nephropathy Among Renal Allograft Recipients From Living Donors is Greater Among Those With Zero HLA Mismatches. Transplantation, 2006, 82, 759-762.	0.5	68
207	Waiting Time and Outcome of Kidney Transplantation in Adolescents. Transplantation, 2006, 82, 1046-1050.	0.5	41
208	Effect on graft and patient survival between shipped and locally transplanted well-matched cadaveric renal allografts in Australia over a 10-year period. Nephrology, 2006, 11, 73-77.	0.7	14
209	The Enigma of Hypertensive ESRD: Observations on Incidence and Trends in 18 European, Canadian, and Asian-Pacific Populations, 1998 to 2002. American Journal of Kidney Diseases, 2006, 48, 183-191.	2.1	22
210	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrology Dialysis Transplantation, 2006, 21, 776-783.	0.4	41
211	Higher Peritoneal Transport Status Is Associated with Higher Mortality and Technique Failure in the Australian and New Zealand Peritoneal Dialysis Patient Populations. Journal of the American Society of Nephrology: JASN, 2006, 17, 271-278.	3.0	159
212	Lymphoproliferative Disease after Renal Transplantation in Australia and New Zealand. Transplantation, 2005, 80, 193-197.	0.5	122
213	Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: Analysis of ANZDATA. Nephrology, 2005, 10, 192-197.	0.7	56
214	Factors influencing reported rates of treated end-stage renal disease. Advances in Chronic Kidney Disease, 2005, 12, 32-38.	0.6	18
215	Interfaces between cardiovascular and kidney disease among Aboriginal Australians. Advances in Chronic Kidney Disease, 2005, 12, 39-48.	0.6	5
216	Obesity is a Risk Factor for Peritonitis in the Australian and New Zealand Peritoneal Dialysis Patient Populations. Peritoneal Dialysis International, 2004, 24, 340-346.	1.1	125

#	Article	IF	CITATIONS
217	The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in Indigenous Australians. Nephrology Dialysis Transplantation, 2004, 19, 678-685.	0.4	60
218	Vascular Access and All-Cause Mortality: A Propensity Score Analysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 477-486.	3.0	384
219	Incidence of end-stage renal disease in overseas-born, compared with Australian-born, non-indigenous Australians. Nephrology, 2004, 9, 247-252.	0.7	21
220	Interpreting incidence trends for treated end-stage renal disease: Implications for evaluating disease control in Australia. Nephrology, 2004, 9, 238-246.	0.7	26
221	Indigenous transplant outcomes in Australia: What the ANZDATA Registry tells us. Nephrology, 2004, 9, S138-S143.	0.7	28
222	Erythropoietic agents, iron and hemoglobin-What happens beyond the trial setting: Observational data from the ANZDATA Registry. Hemodialysis International, 2004, 8, 257-264.	0.4	1
223	Albuminuria: Marker or target in indigenous populations. Kidney International, 2004, 66, S25-S31.	2.6	60
224	Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. American Journal of Kidney Diseases, 2004, 43, 492-501.	2.1	84
225	Vascular access practice patterns in the New Zealand hemodialysis population. American Journal of Kidney Diseases, 2004, 43, 696-704.	2.1	23
226	Long-Term Survival of Children with End-Stage Renal Disease. New England Journal of Medicine, 2004, 350, 2654-2662.	13.9	789
227	Carotid intima-media thickness, cardiovascular risk factors and albuminuria in a remote Australian Aboriginal community. Atherosclerosis, 2004, 177, 423-431.	0.4	37
228	C-reactive protein, cardiovascular risk, and renal disease in a remote Australian Aboriginal community. Clinical Science, 2004, 106, 121-128.	1.8	46
229	Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Peritoneal Dialysis International, 2004, 24, 340-6.	1.1	74
230	Epidemiology of vascular access in the Australian hemodialysis population. Kidney International, 2003, 64, 1893-1902.	2.6	27
231	Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. Kidney International, 2003, 63, S123-S127.	2.6	69
232	Current incidence, treatment patterns and outcome of end-stage renal disease among indigenous groups in Australia and New Zealand. Nephrology, 2003, 8, 42-48.	0.7	85
233	Validation of selfâ€reported cigarette smoking in a remote Australian Aboriginal community. Australian and New Zealand Journal of Public Health, 2003, 27, 57-60.	0.8	39
234	Obesity Is Associated with Worse Peritoneal Dialysis Outcomes in the Australia and New Zealand Patient Populations. Journal of the American Society of Nephrology: JASN, 2003, 14, 2894-2901.	3.0	182

#	Article	IF	CITATIONS
235	Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrology Dialysis Transplantation, 2003, 18, 1555-1561.	0.4	77
236	Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001. Nephrology Dialysis Transplantation, 2002, 17, 2212-2219.	0.4	147
237	ESRD in Australia and New Zealand at the end of the millennium: A report from the ANZDATA registry. American Journal of Kidney Diseases, 2002, 40, 1122-1131.	2.1	63
238	Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients. Kidney International, 2002, 61, 2259-2265.	2.6	21
239	The p53Pro72Arg Polymorphism is Associated with Albuminuria among Aboriginal Australians. Journal of the American Society of Nephrology: JASN, 2002, 13, 677-683.	3.0	20
240	Australians with renal disease: a new national survey. Medical Journal of Australia, 1999, 171, 444-444.	0.8	5
241	PHYSICAL AND BIOCHEMICAL PREDICTORS OF DEATH IN AN AUSTRALIAN ABORIGINAL COHORT. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 618-621.	0.9	26
242	Evaluating data quality in the Australian and New Zealand dialysis and transplant registry using administrative hospital admission datasets and data-linkage. Health Information Management Journal, 0, , 183335832210977.	0.9	1